NASDAQ:NYMX Nymox Pharmaceutical (NYMX) Stock Price, News & Analysis → The #1 Crypto for AI (From Weiss Ratings) (Ad) Free NYMX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.19▼$0.4752-Week Range N/AVolume932,700 shsAverage Volume94,622 shsMarket Capitalization$18.10 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Nymox Pharmaceutical alerts: Email Address Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. About Nymox Pharmaceutical Stock (NASDAQ:NYMX)Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which is in various clinical trials for the treatment of benign prostatic hyperplasia and low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert for detecting tobacco product usage; and TobacAlert for detecting second-hand smoke exposure. In addition, it develops drugs for the treatment of Alzheimer's disease. Nymox Pharmaceutical Corporation was founded in 1989 and is headquartered in Nassau, the Bahamas.Read More Ad Porter & CompanyElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it. NYMX Stock News HeadlinesDecember 27, 2023 | markets.businessinsider.comNymox December 27 Message to ShareholdersDecember 27, 2023 | finanznachrichten.deNymox Pharmaceutical Corporation: Nymox December 27 Message to ShareholdersMay 4, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.November 30, 2023 | finance.yahoo.comNymox Reports California Court Issues Preliminary Injunction Against Defendants Lanham, Riley, Cutler and OthersNovember 22, 2023 | finanznachrichten.deNymox Pharmaceutical Corporation: $250 Million Lawsuit Filed Against AscellaHealth by Nymox Accepted and Summons Issued in California CourtNovember 21, 2023 | markets.businessinsider.com$250 Million Lawsuit Filed Against AscellaHealth by Nymox Accepted and Summons Issued in California CourtNovember 9, 2023 | markets.businessinsider.comNymox Pharmaceutical Corporation Sues AscellaHealth For $250 MillionNovember 6, 2023 | finance.yahoo.comThe Committee to Restore Nymox Shareholder Value Provides Factual Update to Nymox Shareholders Regarding Special MeetingMay 4, 2024 | Colonial Metals (Ad)The asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.November 3, 2023 | financialpost.comNYMOX REPORTS NOTICE: California Court Issued A Temporary Restraining Order Enjoining Lanham, Riley, Cutler And Their Nevada Company After Court Hearing In Santa Ana, California, November 2, 2023October 27, 2023 | benzinga.comNotice: Nymox Informs Its Shareholders Not to Take Calls or Participate in An Unauthorized and Improper Shareholder MeetingOctober 26, 2023 | finanznachrichten.deNymox Pharmaceutical Corporation: Nymox Reports New NYMOZARFEX Marketing Application is Accepted For ReviewOctober 11, 2023 | finance.yahoo.comThe Committee to Restore Nymox Shareholder Value Issues Notice of Special Meeting of Nymox Pharmaceutical ShareholdersOctober 6, 2023 | businesswire.comBahamas Supreme Court Rules in Favor of Committee to Restore Nymox Shareholder Value: Orders Shareholder Meeting, Grants Injunction Freezing CEO SharesSeptember 26, 2023 | finance.yahoo.comNymox Pharmaceutical Corporation (NYMXF)September 25, 2023 | markets.businessinsider.comNymox Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPHAugust 29, 2023 | markets.businessinsider.comNymox Reports Completion of $2 Million Private PlacementJuly 18, 2023 | finanznachrichten.deNymox Pharmaceutical Corporation: Nymox Reports on U.S. Patent IssuancesJuly 18, 2023 | finance.yahoo.comNymox Reports on U.S. Patent IssuancesJuly 16, 2023 | venturebeat.comThe Committee to Restore Nymox Shareholder Value Soundly Rebuts Injurious Allegations Made by Nymox Pharmaceutical Corp Current ManagementJuly 12, 2023 | finance.yahoo.comNymox Announces Appointment Of Patrick Doody as Vice President and Member of the Board of Directors of NymoxJuly 9, 2023 | venturebeat.comRebuttal Letters Issued to Shareholders of NYMOX PHARMACEUTICAL CORP (“NYMX-Q”)July 8, 2023 | finanznachrichten.deNymox Pharmaceutical Corporation: NYMOX UpdateJuly 7, 2023 | financialpost.comNYMOX UpdateJuly 6, 2023 | investorplace.comWhy Is Nymox Pharmaceutical (NYMX) Stock Down 18% Today?July 6, 2023 | seekingalpha.comNymox Pharmaceutical receives potential delisting notice from NasdaqJuly 6, 2023 | msn.comNYMX Tanks after Receiving Delisting NoticeSee More Headlines Receive NYMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2014Today5/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Diagnostic substances Sub-IndustryN/A Current SymbolNASDAQ:NYMX CUSIPN/A CIK1018735 Webwww.nymox.com Phone(800) 936-9669Fax514-332-2227Employees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,589.50% Return on Assets-117.25% Debt Debt-to-Equity RatioN/A Current Ratio0.19 Quick Ratio0.19 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.01) per share Price / BookN/AMiscellaneous Outstanding Shares90,510,000Free Float41,637,000Market Cap$18.10 million OptionableOptionable Beta0.64 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Paul Averback DABP (Age 72)M.D., Founder, Chairman, CEO & Pres Comp: $660kMr. Randall J. Lanham Esq. (Age 59)J.D., Gen. Counsel, Sec., COO & Director Comp: $496.45kMs. Lin DoddQA and Compliance Mang.Mr. Christopher R. RileyChief Financial OfficerKey CompetitorsOncoCyteNASDAQ:OCXCardio DiagnosticsNASDAQ:CDIOTrinity BiotechNASDAQ:TRIBBiomericaNASDAQ:BMRAMyMD PharmaceuticalsNASDAQ:MYMDView All Competitors NYMX Stock Analysis - Frequently Asked Questions How were Nymox Pharmaceutical's earnings last quarter? Nymox Pharmaceutical Co. (NASDAQ:NYMX) issued its earnings results on Friday, November, 14th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter. The biopharmaceutical company had revenue of $0.08 million for the quarter. What other stocks do shareholders of Nymox Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Biocept (BIOC), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MEI Pharma (MEIP), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP) and CTI BioPharma (CTIC). This page (NASDAQ:NYMX) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchCould Your Accounts Be Frozen?Allegiance GoldFW: 234x GainWeiss RatingsThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nymox Pharmaceutical Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.